Journal
BLOOD
Volume 131, Issue 16, Pages 1790-1794Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-11-737411
Keywords
-
Categories
Funding
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grants [R01 DK107309, R01 DK095112, R01 DK090554]
Ask authors/readers for more resources
Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, beta-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available